Cortexyme Stock News

Mainz Biomed MYNZ -23% after secures $22.5M capital raiseCortexyme (CRTX) -21% after announces clinical hold on Atuzaginstat’s IND application.Aptorum Group (APM) -7%

The Company plans to provide additional updates pending continued engagement with FDA.

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

A key clinical setback sent investors to the exits last year.

In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. The post 3 Most-Shorted Stocks at 52-Week Lows to Buy appeared first on

Cortexyme Inc. (NASDAQ:CRTX) traded at $12.81 at close of the session on Tuesday, 12/21/21, made an upward move of 2.81% on its previous days price. Looking at the stock we see that its previous close was $12.46 and the beta (5Y monthly) reads 0.75 with the days price range being $12.19 $13.179. In terms Wall Streets Take On Cortexyme Inc. (NASDAQ: CRTX) Stock. Read More »

Cedar Brook Financial Partners LLC purchased a new stake in shares of Cortexyme, Inc. (NASDAQ:CRTX) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 2,218 shares of the biopharmaceutical companys stock, valued at approximately $203,000. Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Ameritas []

Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec.

CRTX reported partially promising results on October 26, 2021, which have been perceived as a complete failure by the market.

In the last trading session, 1.34 million shares of the Cortexyme Inc. (NASDAQ:CRTX) were traded. Most recently the companys share price was $11.35, and it changed around -$0.96 or -7.80% from the last close, which brings the market valuation of the company to $353.44M. CRTX currently trades at a discount to its 52-week high of Cortexyme Inc. (NASDAQ: CRTX): The Stock We Should Bet On For Economic Growth In The Months To Come Read More »

Cortexyme Inc. (NASDAQ:CRTX) price closed lower on Friday, December 03, dropping -7.39% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile

Cortexyme (NASDAQ:CRTX) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings. Institutional & Insider Ownership 62.7% of Cortexyme shares are held by institutional investors. Comparatively, 27.1% of []

Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.